Drug Development

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Articles

US pharmaceutical and biotechnology research companies invested $58.8 billion in research and development in 2007, according to analyses by the Pharmaceutical Research and Manufacturers of America and Burrill & Company.

R&D Spending by US Pharma and Biotech Firms Reaches Record High

Also, VaxGen and Raven terminate merger agreement, Darren Head appointed CEO of Cytovance, more...

Company and People Notes: Teva to Acquire Bentley Pharmaceuticals, Appointments at Barr, More

The economic case for personalized medicine offers a solution to the industry's recent woes.

A Transformation in the Making

A changing regulatory environment is on the horizon for excipient suppliers and users.

Inside IPEC-EUROPE: Pharmaceutical Excipients—The View from the EU

Moderate growth is projected for the global excipients market. Excipient producers target blends and new grades for improving functionality and performance.

Measuring Excipient-Market Growth

Financial experts share their insights for the performance for innovator drug companies and generic-drug players.

Rocky Outlook for Pharmaceuticals

Michelle Hoffman, editorial director of Pharmaceutical Technology.

The FDA itself issues a cry for help. Is anybody listening?

Message in a Bottle

Excipient producers and industry observers share their perspectives on innovation for excipients.

Tracking the Potential of Excipients

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

Heparin contamination casts a shadow on regulatory oversight of product quality.

FDA Inspection Program Under Scrutiny

Brief pharmaceutical news items for April 2008.

Ingredients